CD105 is important for angiogenesis: Evidence and potential applications

FASEB Journal

Volumn 17, Issue 9, 2003, Pages 984-992

  Duff, Sarah E ^a   Li, Chenggang ^a   Garland, John M ^b   Kumar, Shant ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; HHT1; Tumor prognosis

Indexed keywords

CD1 ANTIGEN; ENDOGLIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; CANCER THERAPY; CELL SURVIVAL; ENDOTHELIUM CELL; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR GROWTH; YOLK SAC;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; MICE; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RADIOIMMUNODETECTION; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR CELL ADHESION MOLECULE-1;

ANIMALIA; CANIS FAMILIARIS; MURINAE;

EID: 0038725471     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.02-0634rev     Document Type: Review

References (80)

1. Folkman, J. (1971) Seminars in Medicine of the Beth Israel Hospital, Boston: tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186
2. Brekken, R. A., Li, C., and Kumar, S. (2002) Strategies for vascular targeting in tumours. Int. J. Cancer 100, 123-130
3. Sanchez-Elsner, T., Botella, L. M., Velasco, B., Langa, C., and Bernabeu, C. (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277, 43799-43808
4. Freemont, A. J., Jeziorska, M., Hoyland, J. A., Rooney, P., and Kumar, S. (2002) Mast cells in the pathogenesis of chronic back pain: a hypothesis. J. Pathol. 197, 281-285
5. Shyu, K. G., Wang, M. T., Wang, B. W., Chang, C. C., Leu, J. G., Kuan, P., and Chang, H. (2002) Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54, 576-583
6. Matsuno, H., Yudoh, K., Uzuki, M., Nakazama, F., and Sawai, T. (2002) Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J. Rheumatol. 29, 890-895
7. Ribatti, D., Cantatore, F. P., Vacca, A., D'Amore, M., Ria, R., Roncali, L., and Pipitore, V. (1998) Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin. Rheumatol. 17, 115-120
8. Quackenbush, E. J., and Letarte, M. (1985) Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukaemia by using monoclonal antibodies. J. Immunol. 134, 1276-1285
9. Gougos, A., and Letarte, M. (1988) Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol. 141, 1925-1933
10. Gougos, A., and Letarte, M. (1988) Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J. Immunol. 141, 1934-1940
11. Cheifetz, S., Bellón, T., Calés, C., Vera, S., Bernabéu, C., Massagué, J., and Letarte, M. (1992) Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 267, 19027-19030
12. Fernandez-Ruiz, E., St.-Jacques, S., Bellon, T., Letarte, M., and Bernabeu, C. (1993) Assignment of the human endoglin gene (END) to 9q34-qter. Cytogenet. Cell Genet. 64, 204-207
13. Pichuantes, S., Vera, S., Bourdeau, A., Pece, N., Kumar, S., Wayner, E., and Letarte, M. (1997) Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50, 265-276
14. Bellón, T., Corbí, A., Lastres, P., Calés, C., Cebrián, M., Vera, S., Cheifetz, S., Massagué, J., and Bernabéu, C. (1993) Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23, 2340-2345
15. Li, C., Hampson, I. N., Hampson, L., Kumar, P., Bernabéu, C., and Kumar, S. (2000) CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J. 14, 55-64
16. Letamendía, A., Lastres, P., Botella, L. M., Raab, U., Langa, C., Velasco, B., Attisano, L., and Bernabéu, C. (1998) Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with betaglycan. J. Biol. Chem. 273, 33011-33019
17. Lastres, P., Letamendía, A., Zhang, H., Rius, C., Almendro, N., Raab, U., López, L. A., Langa, C., Fabra, A., Letarte, M., et al. (1996) Endoglin modulates cellular responses to TGF-β1. J. Cell Biol. 133, 1109-1121
18. Guerrero-Esteo, M., Sanchez-Elsner, T., Letamendia, A., and Bernabeu, C. (2002) Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem. 277, 29197-29209
19. Lastres, P., Martín-Perez, J., Langa, C., and Bernabéu, C. (1994) Phosphorylation of the human-transforming-growth-factor-β-binding protein endoglin. Biochem. J. 301, 765-768
20. Lawler, J., Weinstein, R., and Hynes, R. O. (1988) Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J. Cell Biol. 107, 2351-2361
21. Ruoslahti, E., and Pierschbacher, M. D. (1987) New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497
22. St.-Jacques, S., Cymerman, U., Pece, N., and Letarte, M. (1994) Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology 134, 2645-2657
23. Balza, E., Castellani, P., Zulstra, A., Neri, D., Zardi, L., and Siri, A. (2001) Lack of specificity of endoglin expression for tumor blood vessels. Int. J. Cancer 94, 579-585
24. Guerrero-Esteo, M., Lastres, P., Letamendia, A., Perez-Alvarez, M. J., Langa, C., Lopez, L. A., Fabra, A., Garcia-Pardo, A., Vera, S., Letarte, M., et al. (1999) Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur. J. Cell Biol. 78, 614-623
25. Barbara, N. P., Wrana, J. L., and Letarte, M. (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J. Biol. Chem. 274, 584-594
26. de Caestecker, M. P., Piek, E., and Roberts, S. B. (2000) Role of transforming growth factor β signalling in cancer. J. Natl. Cancer Inst. 92, 1388-1402
27. Li, C., Garland, J. M., and Kumar, S. (2001) Re: Role of transforming growth factor β signalling in cancer. J. Natl. Cancer Inst. 93, 555-556
28. Rius, C., Smith, J. D., Almendro, N., Langa, C., Botella, L. M., Marchuk, D. A., Vary, C. P. H., and Bernabéu, C. (1998) Cloning of the promoter region of human endoglin, the target gene for hereditary haemorrhagic telangiectasia type 1. Blood 92, 4677-4690
29. Graulich, W., Nettelbeck, D., Fischer, D., Kissel, T., and Muller, R. (1999) Cell type specificity of the human endoglin promoter. Gene 227, 55-62
30. Botella, L. M., Sanchez-Elsner, T., Ruis, C., Corbí, A., and Bernabeu, C. (2001) Identification of a critical Spl site within the endoglin promoter and its involvement in transforming growth factor-β stimulation. J. Biol. Chem. 276, 34486-34494
31. Bourdeau, A., Dumont, D. J., and Letarte, M. (1999) A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104, 1343-1351
32. Bourdeau, A., Faughnan, M. E., and Letarte, M. (2000) Endoglin-deficient mice, a unique model to study hereditary haemorrhagic telangiectasia. Trends Cardiovasc. Med. 10, 279-285
33. Bourdeau, A., Faughnan, M. E., McDonald, M.-L., Paterson, A. D., Wanless, I. R., and Letarte, M. (2001) Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol. 158, 2011-2020
34. Adam, P. J., Clesham, G. J., and Weissberg, P. L. (1998) Expression of endoglin mRNA and protein in human smooth muscle cells. Biochem. Biophys. Res. Commun. 247, 33-37
35. Lastres, P., Bellón, T., Cabañas, C., Sanchez-Madrid, F., Acevedo, A., Gougos, A., Letarte, M., and Bernabéu, C. (1992) Regulated expression of human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol. 22, 393-397
36. Kay, N. E., Bone, N. D., Tschumper, R. C., Howell, K. H., Geyer, S. M., Dewald, G. W., Hanson, C. A., and Jelinek, D. F. (2002) B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 16, 911-919
37. Buhring, H. J., Muller, C. A., Letarte, M., Gougos, A., Saalmuller, A., von Agthoven, A. J., and Busch, F. W. (1991) Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5, 841-847
38. Gougos, A., St.-Jacques, S., Greaves, A., O'Connell, P. J., d'Apice, A. J. F., Bühring, H.-J., and Bernabéu, C. (1992) Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol. 4, 83-92
39. Haitjema, T., Westermann, C. J., Overtoom, T. T., Timmer, R., Disch, F., Mauser, H., and Lammers, J. W. (1996) Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch. Intern. Med. 156, 714-719
40. Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S. J., Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A., Guttmacher, A. E., Jackson, C. E., Attisano, L., R, K., Porteous, M. E., and Marchuk, D. A. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13, 189-195
41. McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrell, J., et al. (1994) Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8, 345-351
42. Pece-Barbara, N., Cymerman, U., and Vera, S. (1999) Expression analysis of four endoglin missense mutations suggests that haplotype insufficiency is the predominant mechanism for hereditary haemorrhagic telangiectasia type I. Hum. Mol. Genet. 8, 2171-2181
43. Paquet, M.-E., Pece-Barbara, N., Vera, S., Cymerman, U., Karabegovic, A., Shovlin, C., and Letarte, M. (2001) Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum. Mol. Genet. 10, 1347-1357
44. Shovlin, G. (1997) Molecular defects in rare bleeding disorders: hereditary haemorrhagic telangiectasia. Thromb. Haemost. 78, 145-150
45. Abdalla, S. A., Pece-Barbara, N., Vera, S., Tapia, E., Paez, E., Bernabéu, C., and Letarte, M. (2000) Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum. Mol. Genet. 9, 1227-1237
46. Wang, J. M., Kumar, S., Pye, D., van Agthoven, A. J., Krupinski, J., and Hunter, R. D. (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54, 363-370
47. Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., and Thorpe, P. E. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1, 1623-1634
48. Kumar, P., Wang, J. M., and Bernabéu, C. (1996) CD105 and angiogenesis. J. Pathol. 178, 363-366
49. Bodey, B., Bodey, B., Siegel, S. E., and Kaiser, H. E. (1998) Overexpression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anticancer Res. 18, 3621- 3628
50. van der Kerkhof, P. C., Rulo, H. F., van Pelt, J. P., van Vlijmen-Willems, I. M., and De Jong, E. M. (1998) Expression of endoglin in the transition between psoriatic uninvolved and involved skin. Acta Derm. Venereol. 78, 19-21
51. Kumar, S., Ghellal, A., Li, C., Byrne, G., Haboubi, N., Wang, J. M., and Bundred, N. (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 59, 856-861
52. Arthur, H. M., Ure, J., Smith, A. J. H., Renforth, G., Wilson, D. I., Torsney, E., Charlton, R., Parums, D. V., Jowett, T., Marchuk, D. A., et al. (2000) Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 217, 42-53
53. Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., Boak, B. B., and Wendel, D. P. (1999) Defective angiogenesis in mice lacking endoglin. Science 284, 1534-1537
54. Li, C., Guo, B., Wilson, P. B., Stewart, A., Byrne, G., Bundred, N., and Kumar, S. (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer 89, 122-126
55. Takahashi, N., Kawanishi-Tabata, R., Haba, A., Tabata, M., Haruta, Y., Tsai, H., and Seon, B. K. (2001) Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin. Cancer Res. 7, 524-532
56. Srivastava, A., Laidler, P., Davies, R. P., Horgan, K., and Hughes, L. E. (1988) The prognostic significance of tumor vascularity in intermediate thickness (0.76-4.0mm thick) skin melanoma. A quantitative histologic study. Am. J. Pathol. 133, 419-423
57. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8
58. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84, 1875-1887
59. Horak, E. R., Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K., and Harris, A. L. (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340, 1120-1124
60. Tanigawa, N., Amaya, H., Matsumara, M., and Shimomatsuya, T. (1997) Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas. Br. J. Cancer 75, 566-571
61. Page, D. L., and Jensen, R. A. (1995) Angiogenesis in human breast carcinoma: what is the question? Hum. Pathol. 26, 1173- 1174
62. Lindmark, G., Gerdin, B., Sundberg, C., Påhlman, L., Bergström, R., and Glimelius, B. (1996) Prognostic significance of the microvascular count in colorectal cancer. J. Clin. Oncol. 14, 461-466
63. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., et al. (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A, 2474-2484
64. Wang, J. M., Kumar, S., Pye, D., Haboubi, N., and Al-Nakib, L. (1994) Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. Natl. Cancer Inst. 86, 386-388
65. Miller, D. W., Graulich, W., Karges, B., Stahl, S., Ernst, M., Ramaswamy, A., Sedlacek, H.-H., Müller, R., and Adamkiewicz, J. (1999) Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer 81, 568-572
66. Brewer, C. A., Setterdahl, J. J., Li, M. J., Johnston, J. M., Mann, J. L., and Mcasey, M. E. (2000) Endoglin expression as a measure of microvessel density in cervical cancer. Obstet. Gynecol. 96, 224-228
67. Tanaka, F., Otake, Y., Yanagihara, K., Kawano, Y., Miyahara, R., Li, M., Yamada, T., Hanaoka, N., Inui, K., and Wada, H. (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin. Cancer Res. 7, 3410-3415
68. Akagi, K., Ikeda, Y., Sumiyoshi, Y., Kimura, Y., Kinoshita, J., Miyazaki, M., and Abe, T. (2002) Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 131, S109-S113
69. Wilkstrom, P., Lissbrant, I. F., Stattin, P., Egevad, L., and Bergh, A. (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 268-275
70. Seon, B. K. (2002) Expression of endoglin (CD105) in tumor blood vessels. Int. J. Cancer 99, 310-311
71. Bredow, S., Lewin, M., Hofmann, B., Marecos, E., and Weissleder, R. (2000) Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur. J. Cancer 36, 675-681
72. Fonsatti, E., Jekunen, A. P., Kairemo, K. J. A., Coral, S., Snellman, M., Nicotra, M. R., Natali, P. G., Altomonte, M., and Maio, M. (2000) Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res. 6, 2037-2043
73. Folkman, J. (1995) Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763
74. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1, 27-31
75. Bloemendal, H. J., Logtenberg, T., and Voest, E. E. (1999) New strategies in anti-vascular cancer therapy. Eur. J. Clin. Invest. 29, 802-809
76. Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M., and Barcos, M. (1997) Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res. 3, 1031-1044
77. Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., and Seon, B. K. (1999) Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. 5, 371-382
78. Takahashi, N., Haba, A., Matsuno, F., and Seon, B. K. (2001) Antiangiogenic therapy of established tumors in human skin/ severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61, 7846-7854
79. 125I-labeled anti-endoglin monoclonal antibodies. Int. J. Cancer 82, 737-742
80. Bodey, B., Bodey, B., Jr., Siegel, S. E., and Kaiser, H. E. (1998) Up-regulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anticancer Res. 18, 1485-14500